SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity[1][2].
IC50 & Target
PP2A[1]
体外研究 (In Vitro)
SMAP-2 reduces cell viability of pancreatic ductal adenocarcinoma (PDA) cell lines in a dose-dependent manner[2].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
SMAP-2 significantly reduces abdominal aortic aneurysms (AAA) incidence and aortic dilation in pro-AAA apolipoprotein E-null (ApoE-/-) mice[2]. SMAP-2 (15 mg/kg; i.g.; daily; 6 days a week; for approximately 14 days) has anti-tumor activity in pancreatic cancer mice model[2].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
NSG mice, with PANC89 cells xenograft[2]
Dosage:
15 mg/kg
Administration:
Oral gavage, daily, 6 days a week, for approximately 14 days
Result:
Decreased tumor growth and tumor weight.
分子量
532.57
Formula
C27H27F3N2O4S
CAS 号
1809068-70-9
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Chao Zhang, et al. Abstract 13927: Allosteric Activation of PP2A Inhibits Experimental Abdominal Aortic Aneurysm. 2018. Circulation. 2016;134:A13927.
[2]. Brittany L Allen-Petersen, et al. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2019 Jan 1;79(1):209-219.
